CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题：Research progress on treatment of extramedullary multiple myeloma.
Research progress on treatment of extramedullary multiple myeloma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
通过PubMed进行了系统性文献综述，以总结已发表的关于新型药物和HSCT在EMM中治疗进展的证据。检索了以英文发表的文献来源，使用的检索词为multiple myeloma、extramedullary和treatment。
尽管使用了新型药物和HSCT，EMM患者的长期结局仍然不佳。EMM的标准治疗尚未确立。EMM应作为高危疾病进行管理并据此治疗。 讨论与结论：本综述将提供对当前和新兴治疗策略及其在EMM中疗效的见解。需要在聚焦EMM的大型前瞻性试验中进一步进行亚组分析，以帮助优化治疗。
ABSTRACT Objectives: Extramedullary multiple myeloma (EMM) is a relatively less frequent subentity of multiple myeloma (MM) and is generally considered to be a poor prognostic factor. Novel agents and hematopoietic stem cell transplantation (HSCT) have led to a significant improvement in the progression-free survival and overall survival of patients with MM, but outcomes of EMM remain dismal. Little is known regarding the role of novel therapies in this setting. This review summarizes the current available data regarding the roles of proteasome inhibitors, immunomodulators, monoclonal antibodies, chimeric antigen receptor (CAR)-T cell therapy and HSCT in EMM.
Methods: A systematic literature review through PubMed was conducted to summarize the published evidence on the therapeutic developments of novel agents and HSCT in EMM. Literature sources published in English were searched, using the terms multiple myeloma, extramedullary and treatment.
Results: Long-term outcomes of EMM patients remain dismal despite the utilization of novel agents and HSCT. The standard therapy of EMM has not been established. EMM should be managed as high-risk disease and treated accordingly. Discussion and conclusion: This review will provide an insight on the current and emerging treatment strategies as well as their efficacy in EMM.
Further subgroup analyses in large prospective trials focusing on EMM is needed to help optimize the therapy.
MEMBER ACCOUNT
登录成功会直接打开下一页。
